Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2/PHASE3
2 participants
INTERVENTIONAL
2010-11-30
2012-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Use of Microneedles With Topical Botulinum Toxin for Treatment of Palmar Hyperhidrosis
NCT03203174
Botulinum Toxin Treatment in Craniofacial, Inguinal, Palmar, Plantar and Truncal Hyperhidrosis
NCT01930604
Study of Botulinum Toxin in Patients With Primary Hyperhidrosis
NCT00004480
A Study Using Botulinum Toxin Type A in Patients With Axillary Hyperhidrosis
NCT00168402
Hyperhydrosis Treatment Using Botulinum Toxin
NCT03816046
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Comparator of Hand A intervention vs Hand B
Hand A will receive 100U of BTX-A injected intradermally (SOC) Hand B will receive 100U delivered via iontophoresis.
BTX-A
100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BTX-A
100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 16 and older
* If \<18, parent/legal guardian willing to sign consent and accompany to visits
* Diagnosis of hyperhidrosis disease with a severity score (HDSS) of 3 or 4
* Treatment types of topical antiperspirants, iontophoresis, or systemic anticholinergics have failed to treat
* Able to come to 5 clinical visits during the study period
Exclusion Criteria
* Diagnosis of neuromuscular junctional disorders (e.g. myasthenia gravis or Lambert-Eaton syndrome)
* Diagnosis of dysphagia
* Individuals with surgical implants such as pacemakers, orthopedic hardware, etc.
* Individuals who are Immunocompromised
* Systemic infectious illness or infection at the injection site(s)
* Known hypersensitivity to any ingredient in the formulation of the drug
* Organic cause of hyperhidrosis
* Known allergy to the ingredients in the general anesthesia
* Diagnosis of cardiac/pulmonary issues or disease
* Women who are pregnant or suspected to be pregnant
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Mattioli
UNKNOWN
University of Wisconsin, Madison
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Wisconsin-Madison
Madison, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
H-2009-0193
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.